Squarepoint’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Squarepoint’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,890	Closed	-$79.7K	–	4775
2024 Q1	$79.7K	Buy	+14,890	New	+$103K	﹤0.01%	3829
2021 Q2	–	Sell	-7,573	Closed	-$566K	–	3788
2021 Q1	$566K	Buy	7,573 +4,627	+157%	+$481K	﹤0.01%	1931
2020 Q4	$320K	Buy	2,946 +1,735	+143%	+$158K	﹤0.01%	2161
2020 Q3	$107K	Buy	+1,211	New	+$138K	﹤0.01%	2273
2020 Q2	–	Sell	-1,151	Closed	-$68K	–	2571
2020 Q1	$68K	Sell	1,151 -3,349	-74%	-$227K	﹤0.01%	1697
2019 Q4	$311K	Buy	+4,500	New	+$273K	﹤0.01%	2016

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Squarepoint's SYRS Position: Q2 2024 in Review

Squarepoint sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 14,890 shares — an estimated $79.7K sold.

Squarepoint first reported a position in SYRS in Q4 2019 and held it in 6 quarters. The position peaked at $566K in Q1 2021. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

Squarepoint reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Squarepoint sold 14,890 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $79.7K.
Squarepoint first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
Squarepoint's Syros Pharmaceuticals, Inc. Common Stock position peaked at $566K in Q1 2021.
70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Squarepoint's 13F filing for Q2 2024, filed 14 Aug 2024.